LSV Asset Management increased its stake in shares of MEDNAX Inc (NYSE:MD) by 481.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 262,381 shares of the company’s stock after purchasing an additional 217,281 shares during the period. LSV Asset Management owned approximately 0.29% of MEDNAX worth $8,658,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in MD. First Mercantile Trust Co. boosted its position in shares of MEDNAX by 13.8% in the fourth quarter. First Mercantile Trust Co. now owns 2,275 shares of the company’s stock worth $76,000 after purchasing an additional 275 shares during the period. ETF Managers Group LLC boosted its position in shares of MEDNAX by 18.8% in the fourth quarter. ETF Managers Group LLC now owns 2,404 shares of the company’s stock worth $79,000 after purchasing an additional 381 shares during the period. First Bank & Trust boosted its position in shares of MEDNAX by 14.3% in the fourth quarter. First Bank & Trust now owns 2,808 shares of the company’s stock worth $93,000 after purchasing an additional 351 shares during the period. Gideon Capital Advisors Inc. bought a new position in shares of MEDNAX in the third quarter worth approximately $203,000. Finally, Cerebellum GP LLC boosted its position in shares of MEDNAX by 472.4% in the fourth quarter. Cerebellum GP LLC now owns 5,169 shares of the company’s stock worth $171,000 after purchasing an additional 4,266 shares during the period. 99.76% of the stock is owned by hedge funds and other institutional investors.

MEDNAX stock opened at $36.72 on Tuesday. The firm has a market cap of $3.28 billion, a P/E ratio of 10.46, a price-to-earnings-growth ratio of 1.23 and a beta of 0.69. The company has a current ratio of 1.40, a quick ratio of 1.43 and a debt-to-equity ratio of 0.64. MEDNAX Inc has a 52-week low of $31.68 and a 52-week high of $63.04.

MEDNAX (NYSE:MD) last released its quarterly earnings results on Thursday, February 7th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.83 by $0.09. MEDNAX had a net margin of 7.37% and a return on equity of 10.35%. The company had revenue of $932.70 million for the quarter, compared to the consensus estimate of $910.08 million. During the same quarter in the prior year, the firm earned $0.87 earnings per share. MEDNAX’s revenue was up 2.4% on a year-over-year basis. On average, equities research analysts predict that MEDNAX Inc will post 3.42 earnings per share for the current fiscal year.

A number of equities analysts recently weighed in on MD shares. BMO Capital Markets dropped their target price on shares of MEDNAX from $48.00 to $43.00 and set a “market perform” rating for the company in a research report on Friday, November 2nd. Zacks Investment Research lowered shares of MEDNAX from a “hold” rating to a “sell” rating in a research report on Wednesday, February 6th. ValuEngine lowered shares of MEDNAX from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 1st. UBS Group started coverage on shares of MEDNAX in a research report on Friday, November 16th. They set a “sell” rating and a $37.00 target price for the company. Finally, Mizuho restated a “hold” rating and set a $38.00 target price on shares of MEDNAX in a research report on Monday, January 28th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $42.90.

In other news, insider John C. Pepia sold 2,500 shares of the company’s stock in a transaction dated Tuesday, January 22nd. The shares were sold at an average price of $36.60, for a total value of $91,500.00. Following the transaction, the insider now directly owns 28,583 shares in the company, valued at $1,046,137.80. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 2.70% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Watch List News and is the property of of Watch List News. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/lsv-asset-management-grows-stake-in-mednax-inc-md/2832657.html.

MEDNAX Company Profile

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.

Featured Article: Asset Allocation

Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.